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ABSTRACT: This study provides, for the ﬁrst time, an
evaluation of the physicochemical properties of batch cooling
crystallized mannitol particles combined with how these
properties correlated with the inhalation performance from a
dry powder inhaler (Aerolizer). The results showed that the
type of polymorph changed from β-form (commercial
mannitol) to mixtures of β- + δ-mannitol (cooling crystallized
mannitol crystals). In comparison to mannitol particles,
crystallized at a higher supersaturation degree, a lower degree
of supersaturation favored the formation of mannitol crystals
with a more regular and elongated habit, smoother surface,
higher speciﬁc surface area, higher ﬁne particle content, higher
bulk density, and higher tap density. Cooling crystallized
mannitol particles demonstrated considerably lower salbuta-
mol sulfate−mannitol adhesion in comparison to commercial
mannitol, with a linear reduction as surface roughness
decreased and ﬁnes content increased. Also, mannitol crystals with smoother surfaces demonstrated a reduction in salbutamol
sulfate content uniformity (expressed as %CV) within salbutamol sulfate−mannitol formulations. Despite the diﬀerent physical
properties, all mannitol products showed similar ﬂow properties and similar emission of salbutamol sulfate upon inhalation.
However, mannitol crystals grown from lower supersaturation (reduced roughness and increased ﬁnes) generated a ﬁner
aerodynamic size distribution and consequently deposited higher amounts of salbutamol sulfate on lower stages of the impactor.
Regression analysis indicated linear relationships showing higher ﬁne particle fraction of salbutamol sulfate in the case of
mannitol particles having a more elongated shape, higher ﬁnes content, higher speciﬁc surface area, higher bulk density, and
higher tap density. In conclusion, a cooling crystallization technique could be controlled to produce mannitol particles with
controlled physical properties that could be used to inﬂuence aerosolization performance of a dry powder inhaler product.
1. INTRODUCTION
Drug administration to the respiratory tract is one of the oldest
drug delivery routes.1 Dry powder inhalers (DPIs) are products
that employ both powder technology and device technology.
DPIs are considered attractive delivery devices due to their
several advantages. They are reasonably stable,2 environ-
mentally friendly, easy to formulate compared to pressurized
metered dose inhalers, and have a good potential for systemic
drug delivery.3,4 However, despite its widespread use, high drug
delivery eﬃciency to the lungs is still a major challenge for DPI
formulations.5−7 Therefore, there is increased need for DPI
formulations with improved dispersion and aerosolization
properties.
It is well documented that DPI performance is dependent on
both physical properties of drug particles and carrier particles.
For example, it has been shown that higher amounts of drug
could be delivered to lower airway regions by decreasing the
mean size of either drug particles8 or carrier particles.9,10 The
presence of ﬁne particles on the carrier surface has improved
the inhalation performance of DPI formulations by decreasing
the drug-carrier contact area and consequently reducing drug-
carrier adhesion forces.7,11 Surface morphology of carrier
particles has been modiﬁed in order to obtain improved drug
dispersion properties, where smoother surface6,12 or higher
speciﬁc surface area12,13 produced a higher ﬁne particle fraction
of drug. Manipulating particle shape, for example, elongated
drug particles14 or elongated carrier particles,15 can be used to
enhance particle deposition proﬁles in the respiratory airways.
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Finally, a number of publications have demonstrated that DPI
formulation performance is dependent on drug−drug cohesive
forces and drug-carrier adhesive forces, described as cohesive−
adhesive balance (CAB) (e.g., ref 16).
Mannitol demonstrated promising properties for inhalation
drug delivery through DPIs.6,12 However, little attention has
been paid to mannitol as a potential carrier for DPI
formulations. The aim of the present study was to provide,
for the ﬁrst time, a systemic evaluation of the eﬀect of batch
cooling crystallization (which is a widely used technique for the
production of high-value chemicals)17 on the physicochemical
properties and aerosolization performance of mannitol. Diﬀer-
ent crystallized mannitol powders were prepared and then
characterized in terms of physicochemical properties and in
vitro DPI aerosolization performance. By comparing diﬀerent
mannitol powders, it is possible to evaluate the inﬂuence of
mannitol physical properties on drug inhalation behavior from
dry powder inhalers.
2. EXPERIMENTAL SECTION
2.1. Materials. D-Mannitol and micronized salbutamol sulfate (SS)
[D50% = 1.66 ± 0.06 μm and D90% = 3.14 ± 0.31 μm]
10 were obtained
from Fisher Scientiﬁc, U.K., and LB Bohle, Germany, respectively.
2.2. Preparation of Cooling Crystallized Mannitol Powders.
Supersaturated aqueous solutions of mannitol were prepared at
diﬀerent concentrations: 20, 30, 40, and 50% w/v, respectively. To this
end, diﬀerent amounts of mannitol 5, 7.5, 10, and 12.5 g were
dissolved in deionized water under stirring (250 rpm) at 30, 47, 57,
and 65 °C, respectively, such that the ﬁnal volume solution reaches 25
mL. After being completely dissolved, all solutions were removed from
heating and allowed to settle and cool (uncovered) at ambient
conditions (20 °C, 50% RH) for 96 h (after 96 h no apparent water
could be observed in crystallization media of any samples). Then, each
crystallized mannitol (CrM) powder was harvested and left to dry in
an oven at 60 °C for 24 h. After that, CrM powders were transferred
separately into sealed glass vials until required. For comparison
purposes, commercial mannitol (CM) was used as a control in this
study. In this study, supersaturation was expressed as absolute
supersaturation (ΔC = C/C0) where C is the concentration of the
dissolved mannitol at a given temperature and C0 is the saturation
concentration.
2.3. Selection of Mannitol Particle Size Fraction. Prior to any
investigation, in order to minimize the eﬀect of particle size, all
mannitol powders were mechanically sieved (Endecotts Ltd., England
mechanical shaker and Retsch Gmbh Test Sieve, Germany) for 15 min
to collect 63−90 μm size fractions.6
2.4. Fourier Transform Infrared Spectroscopy (FT-IR). FT-IR
spectra (FT-IR equipment: Perkin-Elmer, USA) were used to
investigate any possible changes in crystallized mannitol that may
have occurred at the molecular level during the crystallization or
drying processes. The scanning range was 450−4000 cm−1 and the
resolution was 1 cm−1.
2.5. Diﬀerential Scanning Calorimetry (DSC). A diﬀerential
scanning calorimeter (DSC7, Mettler Toledo, Switzerland) was used
to characterize DSC traces of all mannitol samples. Samples (4−5 mg)
were heated from 25 to 300 °C in aluminum pans. A purge gas of
nitrogen was passed over the pans with a ﬂow rate of 50 mL/min. In
order to obtain better detection of mannitol polymorphic form, several
heating rates were applied (3 °C/min, 10 °C/min, and 30 °C/min).
Melting points and enthalpies were calculated by the software.
2.6. X-ray Powder Diﬀraction (XRPD). X-ray diﬀractometry of
the commercial mannitol and all recrystallized mannitol were
performed using a Siemens diﬀractometer (Siemens, D5000,
Germany). The cross-section of samples were exposed to X-ray
radiations (Cu Kα) with a wavelength of 1.5406 Å. Samples were
placed into a stainless steel holder and the surface of powder was
leveled manually for analysis. The sample was scanned between 5° and
40° of 2θ with a step size of 0.019° and a step time of 32.5 s.
2.7. Laser Diﬀraction and Image Analysis Optical Micros-
copy. Particle size analysis was conducted using a Sympatec
(Clausthal-Zellerfeld, Germany) laser diﬀraction particle size analyzer
as described elsewhere.12 In addition, quantitative size and shape
optical image analysis were performed using a computerized
morphometric analyzing system (Leica Q Win Standard Analyzing
Software and Leica DMLA Microscope; Leica Microsystems Wetzlar
GmbH, Wetzlar, Germany). For each mannitol sample, a small
amount of powder (about 20 mg) was homogenously scattered onto a
microscope slide and a minimum of 3000 particles were detected and
measured. Several shape descriptors were employed including aspect
ratio (AR) (eq 1), ﬂatness ratio (FR) (eq 2), roundness (eq 3), and
roughness (eq 4):18
=AR length
width (1)
=FR breadth
thickness (2)
= ×
× ×P
roundness
perimeter 1000
4 area
2
(3)
=roughness perimeter
ConvxPerim (4)
2.8. Scanning Electron Microscopy (SEM). Electron micro-
graphs of mannitol, salbutamol sulfate (SS), and mannitol-SS samples
were obtained using a scanning electron microscope (Philips XL 20,
Eindhoven, Netherlands) operating at 15 kV. Prior to observation, the
specimens were mounted on a metal stub with double-sided adhesive
tape and coated under a vacuum with gold in an argon atmosphere.
2.9. Density and Powder Flow Measurements. True density
(Dtrue), bulk density (Dbulk), tap density (Dtap), Carr’s index (CI),
Hausner ratio (HR), and porosity for all mannitol samples were
measured as described in detail elsewhere.7 As using only one method
to measure ﬂowability might give poor estimations,19 ﬂowability for all
mannitol powders was further assessed by measuring the angle of
repose (α). A pile was built by dropping 1 g of each mannitol powder
through a 75 mm ﬂask on a ﬂat surface. The height between the base
where the powder has been poured and the funnel tip was 3 cm. Then,
the angle of repose (α) was calculated using eq 5, where h is the height
of the powder cone and D is the diameter of the base of the formed
powder pile:
α = h
D
tan
2
(5)
2.10. In Vitro Formulation Evaluations. 2.10.1. Preparing
Drug-Carrier Formulations. All mannitol samples were blended with
SS in a ratio of 67.5:1 (w/w) in an aluminum container. This blending
was carried out using a Turbula mixer (Willy A. Bachofen AG,
Maschinenfabrik, Basel, Switzerland) at a constant speed of 100 rpm
for 30 min.
2.10.2. Evaluation of Drug-Carrier Adhesion Forces. Air
depression sieving was employed to assess drug-carrier adhesion
forces. An air jet sieving machine (Copley Scientiﬁc, Nottingham, UK)
was operated at a volume ﬂow that generates negative pressure of 4
KPa. Each formulation (1 g) was placed on top of the 45 μm sieve
(Retsch GmbhTest Sieve, Germany), and four samples (weighing 33
± 1.5 mg corresponding to unite SS dose: 481 ± 22 μg) were removed
from diﬀerent areas of each formulation after diﬀerent functional
sieving times (5, 25, 60, and 180 s). Drug content in each sample was
quantiﬁed using the HPLC method as previously described.6 Adhesion
assessments were conducted in an air-conditioned laboratory (20 °C,
50% RH).
2.10.3. Homogeneity Test. After blending, a minimum of ﬁve
randomly selected samples from diﬀerent positions of formulation
powder bed were taken for assay of SS content. Each sample, weighing
33 ± 1.5 mg, was dissolved in 100 mL of distilled water in a volumetric
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ﬂask and the amount of SS was determined using HPLC. For each
formulation, average drug content (% potency, nominal SS dose) was
calculated and drug content homogeneity was expressed as percentage
coeﬃcient of variation (% CV).
2.10.4. In Vitro Deposition Study. After blending, each formulation
was ﬁlled manually in hard gelatin capsules (size 3) such that each
capsule contained 33 ± 1.5 mg of formulation corresponding to 481 ±
22 μg of SS, which was the same dose as in commercially available
Ventolin Rotacaps. After ﬁlling, capsules were stored for equilibration
in sealed glass vials at ambient conditions (20 °C, 50% RH) for at least
24 h prior to investigation. Pulmonary drug deposition proﬁles of
diﬀerent formulations were assessed in vitro using a multi stage liquid
impinger (MSLI) equipped with a USP induction port (Copley
Scientiﬁc, Nottingham, UK) at a ﬂow rate of 92 L/min as explained in
detail elsewhere.6 Each deposition experiment involved the actuation
of 10 capsules and was repeated a minimum of three times. Several
parameters were employed to characterize deposition proﬁles for all
formulations under investigation,6 including percent emission (EM),
impaction loss (IL), mass median aerodynamic diameter (MMAD),
and geometric standard deviation (GSD). Fine particle dose
Figure 1. DSC traces, FT-IR spectra, and/or PXRD patterns for commercial mannitol (CM) and cooling crystallized mannitol (CrM) from 20%,
30%, 40%, and 50% w/v solutions.
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(FPD≤5 μm) was calculated by interpolation of drug aerodynamic size
distributions obtained by MSLI deposition proﬁles. FPF≤5 μm was
calculated as the percent ratio of FPD≤5 μm to RD. Eﬀective inhalation
index (EI) and theoretical aerodynamic diameter (Dae) were calculated
using eqs 6 and 7 respectively10 (where De is geometric mean
diameter, ρ is true density, and x is the dynamic shape factor for
nonspherical particles which could be assumed as 1):
= × μ≤EI (EM FPF )5 m 1/2 (6)
ρ= ×D D
xae e (7)
2.11. Statistical Analysis. One-way analysis of variance
(ANOVA) was applied (where appropriate) to compare results in
this study. P values less than 0.05 were considered as indicative of
statistically signiﬁcant diﬀerence.
3. RESULTS AND DISCUSSION
3.1. Crystallization Procedure. The crystal physical
properties are profoundly inﬂuenced by rate of crystallization
which is mainly governed by supersaturation.20 The eﬀect of
absolute supersaturation (which is 3, 13, 23, and 33 for
mannitol crystallized from 20%, 30%, 40%, and 50% (w/v)
solutions, respectively) on cooling crystallized mannitol (CrM)
particle properties was studied (the saturated mannitol
concentration was 17% w/v at 21 °C). Following preparation
of all mannitol saturated solutions, none of the CrM particles
could be observed immediately in the crystallization media. In
fact, slow crystallization rate is the main disadvantage of cooling
crystallization technique,21 due to the large width of metastable
zone. Nevertheless, slow cooling is advantageous in terms of
attaining maximum product yield, minimum agglomeration,22
fewer defects in the crystal lattice,23 and improved product
purity.24 As the supersaturation increases induction time
(deﬁned as the time elapsing between cooling and the
formation of detectable crystals) decreases whereas mannitol
crystal growth rate increases. For each medium, the longer the
mannitol supersaturated solutions were kept the greater the
amounts of crystals were observed to form at the expense of
water amounts. No water could be visualized in the
crystallization media after 24 h in the case of 33 and 23
absolute supersaturations, but it was after 96 h in the case of 13
and 33 absolute supersaturations. Crystal yields were high and
did not show signiﬁcant diﬀerences due to supersaturation
degree (97− 98%).
3.2. Solid State Characterization. At slow heating rates
(3 and 10 °C/min), all mannitol samples showed similar DSC
trances having one endothermic transition around 167 ± 1 °C
(representing melting of either α-mannitol or β-mannitol which
are not distinguishable from each other by DSC).25 However,
FT-IR spectra of commercial mannitol (CM) exhibited the
spectrum of the reference β-mannitol pointed out in previous
studies,26 having the speciﬁc diagnostic bands at 929, 959, and
1209 cm−1 (Figure 1). FT-IR of CrM products exhibited both
β-mannitol diagnostic bands and delta mannitol (δ-mannitol)
diagnostic band at 967 cm−1,26,12 indicating the presence of
both β-mannitol and δ-mannitol (Figure 1).
At higher heating rates (30 °C/min), DSC traces of CrM
samples displayed two-phase transitions (Figure 1). The ﬁrst
transition is characterized by an endothermic event at 157 °C,
which could be related to melting of δ-mannitol,26,12 followed
by conversion of δ-mannitol form (enantiotropic toward α- and
β-) to either β-mannitol form (monotropic toward α-) or α-
mannitol form (Figure 1). Comparing δ-mannitol melting
enthalpies of all mannitol samples suggested that mannitol
crystallized from lower concentrations contained a higher
quantity of δ-mannitol. The second transition corresponds to
the melting of either α-mannitol or β-mannitol phase (Figure
1). The FT-IR and DSC results obtained for CM was
supported by the PXRD pattern of CM (Figure 1). The
PXRD pattern corresponds to that of β-mannitol form with its
diagnostic peaks at 10.56°, 14.71°, 23.4°, 29.5°, and 38.8°.26
The PXRD pattern of CrM-20% exhibited both β-mannitol
diagnostic peaks and δ-mannitol diagnostic peaks at 9.74° and
22.2°,15,26 conﬁrming the presence of both β-mannitol and δ-
mannitol (Figure 1). In conclusion, CM was pure β-mannitol
whereas CrM particles crystallized as mixtures of β-mannitol
and δ-mannitol. However, the presence of δ-mannitol within
CrM samples could not be detected by DSC running at slow
heating rates. Both β- and δ-mannitol forms are known to be
chemically or physically stable for at least 5 years in dry
atmosphere (25 °C). δ-Mannitol has a diﬀerent structure to β-
mannitol and would be expected to have diﬀerent preferred
morphology and surface properties as discussed in the Particle
Shape Analysis section of the article.
3.3. Particle Size Measurements. Although all mannitol
samples were carefully sieved in an identical method, CrM
powders showed smaller PSDs (Figure 2a), higher ﬁne particle
mannitol content (FPM<5 μm and FPM<10 μm), higher volume
speciﬁc surface area (SSAv), and higher span than CM (Figure
2b). This could be attributed to variations between diﬀerent
mannitol products in terms of crystal habits as shown later.
Figure 2. Cumulative particle size distribution (a); (yellow bars)
volume speciﬁc surface area (SSAv), ﬁne mannitol particles (●) less
than 5 μm (FPM<5 μm) or (○) less than 10 μm (FPM<10 μm), and (▲)
span (b) for diﬀerent 63−90 μm sieved mannitol samples: commercial
mannitol (CM) and cooling crystallized mannitol (CrM) from 20%,
30%, 40%, and 50% (w/v) solutions (mean ± SD, n = 5).
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Generally, mannitol crystals grown from lower supersaturations
demonstrated higher FPM<5 μm, higher FPM<10 μm, and higher
SSAv (Figure 2b). This could be attributed to a possible
increased number of particle agglomerates with increasing
supersaturation (due to increased nucleation rates).
Statistical analysis on all mannitol samples showed that SSAv
has a high correlation with VMD (−0.95), FPM<5 μm (1.00),
FPM<10 μm (0.99), and span (0.96) conﬁrming a higher SSAv for
mannitol particles with smaller VMD, higher FPM content, and
higher span. Mannitol powders crystallized from higher
supersaturations have narrower (more homogeneous) size
distributions as indicated by a smaller span (Figure 2b). This
was in agreement with previous studies27,28 and could be
attributed to increased driving forces of nucleation in the case
of solutions with higher supersaturations.
3.4. Particle Shape Characterization. Representative
microscopic images and SEM photographs for all mannitol
powders inspected in this study are shown in Figures 3 and 4,
respectively. It can be observed that particle shape and surface
topography of diﬀerent mannitol powders varied considerably
(Figures 3 and 4). In fact, as the crystallization rate in the
vicinity of the growing crystal surfaces is dependent on the
degree of supersaturation, any change of supersaturation is
expected to have an eﬀect on the crystal morphology. These
diﬀerences in carrier particle morphology are anticipated to
have a signiﬁcant eﬀect on DPI performance.15
Aspect ratio (AR) and ﬂatness ratio (FR) are the
fundamental ﬁrst-order descriptors of particle form. AR/FR is
a shape descriptor helpful to describe the overall particle shape.
All CrM particles showed higher AR/FR than CM (Figure 3a),
indicating that CrM particles have more elongated habit. This
might be related to the presence of δ-mannitol within CrM
particles (Figure 1) as δ-mannitol crystals have elongated
(oblong) unit cell and crystal habit.29 This was further
Figure 3. (a) Aspect ratio/ﬂatness ratio (AR/FR) (□), and representative microscope images, for diﬀerent 63−90 μm sieved mannitol powders:
commercial mannitol (CM) (b) and cooling crystallized mannitol (CrM) from 20% (c), 30% (d), 40% (e), and 50% (w/v) (f) solutions.
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supported by representative microscope images (Figure 3b−f)
and SEM photographs (Figure 4b−f). Comparing AR/FR
values of all CrM particles showed that there was a linear
inverse relationship between AR/FR values and mannitol
supersaturation degree (linear, r2 = 1, AR/FR = −0.0498
supersaturation +7.2008) (Figure 3a). This demonstrates that a
low degree of mannitol supersaturation favored the formation
of needle-shaped crystals, whereas a high degree of super-
saturation favored the formation of ﬂat shaped-crystals. This
could be attributed to the fact that the eﬀect of supersaturation
on growth kinetics is diﬀerent for each crystallographic face.30
At low supersaturation, crystal growth of mannitol by hydrogen
bonding is expected to be favored in one direction (“preferred”
axis which has the highest free hydrophilic groups) leading to
the formation of more elongated crystals (δ-mannitol).
However, at high supersaturation, secondary nucleation might
become more dominant on crystal faces to the “preferred” axis
restraining any further primary growth along this axis and as a
result mannitol crystal elongation decreases as supersaturation
increases.
Roundness is a second-order shape descriptor reﬂecting
variations at particle corners, whereas roughness is a third-order
shape property independent of both ﬁrst-order (e.g., AR and
FR) and second-order (e.g., roundness) shape descriptors. CrM
particles showed smaller roundness and smaller roughness than
CM (Figure 4a), which is indicative of their more regular shape
and smoother surface texture. Mannitol crystals grown from
lower supersaturations have smaller roundness and smaller
roughness indicating their more regular shape and smoother
surface topography (Figure 4a). This was further supported by
SEM photographs where, unlike CM (in which large
protuberances could be observed forming angular edges (Figure
4b)), CrM particles have subrounded-subangular shape (Figure
4c−f). Moreover, visualization of surface topography demon-
strated that CM has a wrinkled fractured surface with a higher
degree of roughness (Figure 4b), whereas CrM particles have a
relatively smoother surface with less irregularities (Figure 4c to
3f).
The mechanism of crystal growth is dependent on the degree
of supersaturation. For example, spiral growth theory is more
relevant to the crystal growth from low supersaturations,31
whereas classical crystal growth theory might happen for the
crystal growing from high supersaturations.32 At lower levels of
supersaturation, kinetics of crystallization becomes slow and
this favors ordered (regular) crystal growth patterns, small
surface nuclei, and perfect lattice on crystal surface, generating
crystals with regular shape and smoother surface. On the
contrary, higher supersaturation induces accelerated nucleation
(by lowering the interfacial energy in the solid-solution
interface) and secondary (heterogeneous) nucleation growth,
which generate crystals with less regular shape and rougher
surfaces. In conclusion, crystal habit is profoundly inﬂuenced by
the rate of crystallization. Mannitol crystals grown from lower
supersaturations have a more regular shape, more elongated
shape, and smoother surface topography. CM particles showed
the roughest surface topography and the lowest degree of shape
regularity and shape elongation.
3.5. Density and Flowability Assessments. All CrM
particles showed considerably smaller Dtrue than CM (1.48 ±
0.01 g/cm3 versus 1.52 ± 0.00 g/cm3), suggesting that δ-
mannitol might have smaller Dtrue than β-mannitol. Also, CrM
particles demonstrated smaller Dbulk, and smaller Dtap than CM
(Figure 5). Mannitol powders crystallized from higher
supersaturations demonstrated smaller Dbulk (linear, r
2 =
Figure 4. (a) (Δ) Roundness, (●) roughness; SEM images of diﬀerent 63−90 μm sieved mannitol powders: commercial mannitol (CM) (b) and
cooling crystallized mannitol (CrM) from 20% (c), 30% (d), 40% (e), and 50% (w/v) (f) solutions.
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0.9557) and smaller Dtap (linear, r
2 = 0.9151) (Figure 5).
Conversely, porosity obtained for CrM powders was higher
than CM (69.4−74.6% versus 64.2%), and mannitol powders
crystallized from higher supersaturations showed higher
porosity (linear, r2 = 0.9368, ﬁgure not shown). This indicates
increased interparticulate cohesive forces for CrM particles with
increasing supersaturation.
Unlike Dtrue (particle characteristic), Dbulk, Dtap, and porosity
are powder characteristics related to spaces and voids within the
powder. Lower porosity, higher Dbulk, and higher Dtap for
mannitol powders crystallized from lower supersaturations
could be attributed to a higher degree of interparticulate
average contact points within the powder due to a higher
content of ﬁne particles (Figure 2b), more regular shape
(smaller roundness), and smoother particle surface (Figure 4).
Despite their diﬀerence in terms of density, all sieved mannitol
powders showed statistically similar CI (16.0 ± 2.2% − 19.0 ±
2.5%), similar HR (1.15 ± 0.01 − 1.23 ± 0.02), and similar α
(35.2 ± 4.8° − 40.3 ± 5.2°) corresponding to good to fair ﬂow
properties.
3.6. DPI Formulation Assessments. 3.6.1. SS-Mannitol
Formulation Evaluation by SEM. SEM photographs of SS and
all SS-mannitol formulations are shown in Figure 6. SEM
images of SS particles (Figure 6a) were observed to be less than
5 μm in size exhibiting a high degree of agglomeration and the
typical rectangular (or rod) shape pointed out in previous
studies.13 In the case of SS-mannitol formulations (Figure 6b−
f), SS particles could be morphologically detected as, generally,
single (individual) particles adhered to large mannitol particle
surfaces. This conﬁrms the formation of SS-mannitol interactive
ordered mixtures suitable for DPI systems. By observing surface
topography, ﬁne particles are easily visible on the surface of
larger mannitol particles (Figures 6b−f), which is in agreement
with PSD measurements (Figure 2). These ﬁnes correspond to
“intrinsic (not added)” ﬁne mannitol particles attached to the
surface of large mannitol particles which could not be removed
by sieving. Compared to SS-CM formulation, SS-CrM
Figure 5. (○) Bulk density (Dbulk) and (●) tap density (Dtap) for
diﬀerent 63−90 μm sieved mannitol powders: commercial mannitol
(CM) and cooling crystallized mannitol (CrM) from 20%, 30%, 40%,
and 50% (w/v) solutions (mean ± SD, n ≥ 5).
Figure 6. SEM images for micronized salbutamol sulfate alone (SS) (a), and diﬀerent SS-mannitol formulations containing diﬀerent 63−90 μm
sieved mannitol powders: commercial mannitol (CM) (b) and cooling crystallized mannitol (CrM) from 20% (c), 30% (d), 40% (e), and 50% (w/
v) (f) solutions. FPA: ﬁne particle aggregates (SS and ﬁne particle mannitol). Arrows indicate SS particles.
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formulations exhibited a decreased number of SS particle
entrapped in macroscopic depressions on the mannitol surface
(Figure 6), which is likely to facilitate SS detachment from CrM
surfaces during inhalation. Also, SS-ﬁne mannitol aggregates
(FPA) were observed in the case of SS-CrM formulations
(Figure 6c−f). These FPA are believed to be formed at the
expense of SS-mannitol interactive mixtures and are expected to
improve DPI performance.
3.6.2. SS-Mannitol Adhesion Assessments. Upon air jet
sieving of formulations, small SS particles are expected to
detach from coarse mannitol particles. Amounts of SS
remaining on top of the 45 μm sieve after subjecting all
formulations to diﬀerent functional sieving times are given in
Table 1. For all formulations, amounts of SS decreased as
sieving time increased. This conﬁrms that all formulations were
ordered mixtures. Assuming the particle adhesion force is
equivalent to the particle detachment force, less amounts of SS
collected from the top of the 45 μm sieve is indicative of weaker
SS-mannitol adhesion. Among all formulations, the highest
amounts of SS after all sieving times were obtained for SS-CM
formulation, whereas the lowest amounts of SS were obtained
for SS-CrM-20% formulation (Table 1). This indicates that
mannitol crystals grown from lowest supersaturation generated
the lowest SS-mannitol adhesion forces, whereas the highest
adhesion forces were obtained in the case of CM. Less SS-
mannitol adhesion could be attributed to weaker SS-mannitol
physical interactions. It is known that particle surface properties
aﬀect the drug-carrier contact geometry and thus has a
substantial impact on drug-carrier adhesion. Figure 7 shows
that SS-mannitol adhesion forces decreases as mannitol surface
smoothness, shape elongation (AR/FR), and/or ﬁnes content
(FPM<5 μm) increases. This could be ascribed to entrapment of
drug particles in carrier surface indentations in the case of
carriers with a rougher surface.6,12 Also, FPM on coarse
mannitol surface may decrease both SS-mannitol contact area
and SS-mannitol press-on adhesive forces generated during
blending.
3.6.3. Formulation Homogeneity Test. Percent potency and
percent CV obtained from formulations containing diﬀerent
mannitol powders are given in Table 1. Formulations
containing CrM produced decreased potency than the CM
formulation (Table 1). This could be due to reduced SS-
mannitol adhesion in the case of CrM compared to CM (as
proven previously), which might lead to increased amounts of
“lost drug” during handling processes (e.g., mixing, storage, and
capsule ﬁlling). SS-CrM formulations produced reduced drug
content homogeneity than SS-CM formulation as indicated by
higher % CV (Table 1). An indirect linear correlation (r2 =
0.9952) was established between mannitol roughness and %
CV of SS (Figure 8) suggesting that carriers with a rougher
surface produce improved drug content homogeneity. Such an
outcome could be explained as a higher degree of mannitol
surface roughness reinforces the SS-mannitol adhesion (Figure
7).
3.6.4. In Vitro Aerosolization Studies. Mass distribution of
SS deposited on I + M, IP, and diﬀerent MSLI stages obtained
from diﬀerent formulations varied considerably for SS-mannitol
formulations (Figure 9a). All CrM powders deposited higher
amounts of SS on the throat (IP) (Figure 9a). Formulations
Table 1. Percent Potency and Coeﬃcient of Variation (Mean Potency (CV)) and Percent Amounts of Salbutamol Sulphate
Remained on Top of the 45 μm Sieve (mean (SD), n ≥ 3) after Diﬀerent Functional Sieving Times for DPI Formulations
Containing Diﬀerent 63−90 μm Sieved Mannitol Powders: Commercial Mannitol (CM) and Cooling Crystallized Mannitol
(CrM) from 20%, 30%, 40%, and 50% (w/v) Solutions
sieving time
mannitol product 0 s: % potency(CV) 5 s 25 s 60 s 180 s
CM 93.9 (1.76) 89.7 (2.9) 78.9 (2.9) 73.2 (3.2 46.7 (2.6)
CrM-20% 76.8 (9.44) 35.5 (3.6) 13.4 (1.1) 9.9 (0.0) 9.1 (0.8)
CrM-30% 91.5 (9.36) 62.3 (6.2) 43.6 (4.3) 35.7 (0.8) 24.5 (0.4)
CrM-40% 67.6 (9.26) 67.4 (9.9) 18.2 (0.8) 12.2 (0.9) 12.6 (1.4)
CrM-50% 90.6 (6.30) 78.3 (6.7) 34.2 (4.9) 15.7 (3.1) 8.4 (0.0)
Figure 7. Percent amounts of salbutamol sulfate remaining on top of
the 45 μm sieve after 5 s functional sieving time (mean ± SD, n ≥ 3),
in relation to (●) mannitol surface roughness, (⧫) aspect ratio/
ﬂatness ratio (AR/FR), and (Δ) ﬁne mannitol particles (FPM<5 μm).
Figure 8. Relationship between mannitol surface roughness and
coeﬃcient of variation (% CV) in salbutamol sulfate content for DPI
formulations containing diﬀerent mannitol powders: commercial
mannitol (CM) and cooling crystallized mannitol (CrM) from 20%,
30%, 40%, and 50% (w/v) solutions.
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containing mannitol crystals grown from lower supersaturations
deposited smaller amounts of SS on MSLI stage 1, but higher
amounts on MSLI stage 2, stage 3, and stage 4 (Figure 9a).
When compared with laser diﬀraction data, aerodynamic PSD
data indicated that SS particles were not suﬃciently dispersed
into individual particles (Figure 9b). This could be attributed to
SS particle cohesiveness and/or inadequate inhaler device
dispersing eﬃciency to recover primary PSD of SS (which was
supported by SEM images showing FPA (Figure 6c−f)). Figure
9b shows that mannitol crystals grown from lower super-
saturations generated smaller aerodynamic PSDs of SS (closer
to primary PSD of pure SS powder). Moreover, the slope of
aerodynamic PSD curves, named as constant K,15 which
apparently reﬂects the tendency of SS particles to penetrate
deeper into lower lung airways, was a linear function (r2 =
0.9887) to mannitol concentration used during crystallization
(Figure 9c). Such data indicate that mannitol crystals grown
from lower supersaturations deliver higher amounts of SS to
lower airways, indicating their preferred aerodynamic properties
since β-receptors are mainly located in the lower airway
regions.33
However, all formulations demonstrated similar (P > 0.05)
MMAD (3.0 ± 0.2 - 3.4 ± 0.2 μm, n ≥ 3) and similar GSD
(2.11 ± 0.04 − 2.18 ± 0.03, n ≥ 3) of SS. This conﬁrms that
drug aerosolization performance could not be predicted,
necessarily, from MMAD and GSD alone. Moreover, this
indicates a similar degree of SS agglomeration within all
formulations, suggesting variations of SS inhalation behavior
between diﬀerent formulations could be attributed to diﬀerent
SS-mannitol adhesion properties not diﬀerent SS-SS cohesion
properties.
By comparison, SS showed the following rank order in terms
of size: De (1.66 ± 0.06 μm) < Dae (2.2 ± 0.2 μm) < MMAD
(3.26 ± 0.18 μm). High MMAD values, in comparison to Dae,
value could be attributed to cohesion between SS particles in
the dry powder state (Figure 6a) and the formation of FPA
within SS-mannitol formulations (Figure 6c−f). GSD measure-
ments of SS obtained from all formulations were around 2 (2.1
± 0.0), which is indicative of polydisperse aerodynamic size
distribution.
Comparing SS-CrM formulations demonstrated higher
amounts of SS deposited on the throat (IP) in the case of
CrM crystals with rougher surface (linear, r2 = 0.8299) and
higher FPM<5 μm content (linear, r
2 = 0.8985) (Figure 10). This
could be explained by the “active sites” theory, as in the case of
increased amounts of FPM<5 μm; they have higher possibility to
occupy the active sites on mannitol surfaces leaving SS particles
to agglomerate or to form SS-FPM<5 μm aggregates (FPA)
(Figure 6c−f) that have a higher probability to deposit on the
throat by inertial impaction.
All formulations produced similar EM of SS (94.7 ± 1.3 −
96.3 ± 0.2%, n ≥ 3, P > 0.05), which could be ascribed to
similar ﬂowability of all mannitol powders (section 3.5).
Mannitol concentration used during crystallization was
indirectly proportional to FPF≤5 μm (linear, r
2 = 0.9887) and
EI (linear, r2 = 0.9948) but directly proportional to IL (linear, r2
= 0.988) (Figure 11). This indicates that mannitol crystals
grown from lower supersaturations can have better perform-
ance in DPI formulations containing salbutamol sulfate, as in
theory, FPF≤5 μm refers to the percentage fraction of the drug
that is pharmacologically active.34 The FPF≤5 μm exhibited a
decreasing trend (linear, r2 = 0.9041) with increasing SS
amounts remaining after 5 s of air jet sieving (Figure 12a). This
relationship is important as it conﬁrms that the enhanced
aerosolization performance in the case of mannitol crystals
grown from lower supersaturations was due to a lower degree
of SS-mannitol adhesion forces.
As discussed previously, all formulations were prepared at the
same blending conditions, contain the same batch of SS, and
Figure 9. Mass distribution (a), aerodynamic size distribution before
(solid line) and after aerosolization (b), and the relationship between
constant K and mannitol concentration (c) for salbutamol sulfate
when aerosolizing DPI formulations containing SS blended with
diﬀerent 63−90 μm sieved mannitol powders: commercial mannitol
(CM) and cooling crystallized mannitol (CrM) from 20%, 30%, 40%,
and 50% (w/v) solutions.
Figure 10. Amounts of salbutamol sulfate deposited on the throat (IP)
(mean ± SD, n ≥ 3) in relation to mannitol surface roughness (●)
and ﬁne particle mannitol (FPM<5 μm) (Δ).
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contain mannitol powders with similar ﬂow properties, yet
considerably diﬀerent morphologies. Interestingly, a direct
linear relationship (r2 = 0.981) was established between
mannitol AR/FR and FPF≤5 μm (Figure 12b) demonstrating
that carrier crystals with more elongated and less ﬂattened habit
produced better DPI performance. It is believed that more
elongated/less ﬂattened carrier particles will result in less drug-
carrier contact points or less stable contact area35,36 and thus
fewer drug-carrier adhesion properties.37 Also, elongated
mannitol particles are expected to produce decreased press-
on adhesive forces during the blending process (Figure 13).
Furthermore, elongated mannitol crystals are expected to have
more ability to stay airborne in an airﬂow (than isometric
particles that have the same geometric size) and therefore they
have more ability to travel further in lung airways. This will
encourage SS particles to detach from the mannitol surface due
to increased “eﬀective” aerosolization time (Figure 13). Also,
this concords with previous studies; correlations between
FPF≤5 μm with mannitol carrier physical properties showed
direct linear relationships with FPM<5 μm (r
2 = 0.9203),38
(Figure 13b), SSAv (r
2 = 0.9192),6 Dbulk (r
2 = 0.906), and Dtap
(r2 = 0.8649) (Figure 13c).7 Finally, it has to be noted that
PSD, solid state, and in vitro inhalation performance for all
mannitol samples and/or formulations were not profoundly
aﬀected when stored in sealed glass vials in ambient conditions
for a minimum of 16 months (data not shown).
4. CONCLUSION
This study demonstrated that, controlled cooling crystallization
of mannitol could be an attractive technique to allow the
engineering of mannitol crystals with desired physicochemical
properties and improved inhalation performance. The initial
supersaturation degree used during crystallization of mannitol
appears to be a critical factor in the control of the
physicochemical properties. Mannitol crystals grown from low
supersaturation grows as needle-like crystals whose length
decreases linearly with increasing supersaturation. Furthermore,
speciﬁc surface area, ﬁne particles content, surface smoothness,
bulk density, and tap density of mannitol crystals increase with
decreasing supersaturation degree. Improved inhalation per-
formance was obtained for formulations containing mannitol
crystallized from lower supersaturations due to reduced
salbutamol sulfate-mannitol adhesion. Mannitol crystals
grown from 20% w/v solutions demonstrated the highest
speciﬁc surface area, the highest ﬁne particles content, the
highest degree of shape elongation, and the smoothest surface
topography produced the best DPI inhalation performance in
terms of highest ﬁne particle fraction≤5 μm of 33.8 ± 1.2%
compared to 14.9 ± 1.1% for the commercial grade. In this
study, the crystallization work has been completed at a small
scale and using uncontrolled cooling rates. Therefore, more
crystallization development work would be valuable to fully
determine the beneﬁts of the cooling crystallization approach.
Nevertheless, this study gives comparative information and
highlights that mannitol crystal grown from low supersaturation
would be desirable for DPI formulations, mainly due to their
elongated habit, smoother surface, and higher “intrinsic” ﬁnes
content.
Figure 11. (●) Fine particle fraction (FPF≤5 μm), (○) impaction loss
(IL), and (Δ) eﬀective inhalation index (EI) (mean ± SD, n ≥ 3)
obtained from formulations containing diﬀerent 63−90 μm sieved
mannitol powders: commercial mannitol (CM) and cooling crystal-
lized mannitol (CrM) from 20%, 30%, 40%, and 50% (w/v) solutions.
Figure 12. FPF of salbutamol sulfate (SS) in relation to (◊) % SS
remained on the 45 μm sieve following 5 s air jet sieving (a), (●) ﬁne
particle mannitol (FPM<5 μm), (⧫) aspect ratio/ﬂatness ratio (AR/FR)
(b), (□) bulk density (Dbulk), (Δ) tap density (Dtap), and (○) volume
speciﬁc surface area (SSAv) (c).
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